Centre National De La Recherche Scientifique

Universite Claude Bernard – Lyon1

Hospices Civils De Lyon

Centre Leon Berard

Institut National De La Sante Et De La Recherche Medicale

Institut National De La Sante Et De La Recherche Medicale (inserm)

Les Hospices Civils De Lyon

Serge Lebecque

Toufic Renno

Isabelle Coste-Invernizzi

Stéphane Giraud

Alain Kfoury

The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Benzoimidazole derivatives as anticancer agents

The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.

Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction

Growing community of inventors

Civrieux d'Azergues, France

Serge Lebecque